Eye-Aging Reprogramming Trial Doses First Patient in Vision Rescue Study
Life Biosciences dosed the first patient in a small, safety-focused trial of ER-100, a gene therapy designed to reset epigenetic marks in retinal ganglion cells to reverse aging-like changes and potentially restore vision in open-angle glaucoma or NAION. Delivered by a virus and activated by a specific antibiotic, the study will enroll up to 18 participants and follow them for years, attracting both optimism about aging biology and warnings about safety risks and uncertain efficacy.